Volume 6.35 | Sep 11

Cord Blood News 6.35 September 11, 2014
Cord Blood News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  CBN on Twitter
Heterogeneous Functions of Perinatal Mesenchymal Stromal Cells Require a Pre-Selection before Their Banking for Clinical Use
Researchers compare adult BM-MSCs with MSCs from perinatal tissues (cord blood, umbilical cord, amnion and chorion) on their in vitro immunological and stromacytic efficiencies under different priming conditions. [Stem Cells Dev] Abstract
Take the "if" out of "diff": Reduce variability when differentiating to hematopoietic cells
PUBLICATIONS (Ranked by impact factor of the journal)
Multiple Injections of Human Umbilical Cord-Derived Mesenchymal Stromal Cells through the Tail Vein Improve Microcirculation and the Microenvironment in a Rat Model of Radiation Myelopathy
An irradiated cervical spinal cord rat model was generated. Umbilical cord-derived mesenchymal stromal cells were injected through the tail vein at 90, 97, 104 and 111 days post-irradiation. Behavioral tests were performed using the forelimb paralysis scoring system, and histological damage was examined using Nissl staining. [J Transl Med] Abstract | Full Article

Influence of Nuclear Blebs and Micronuclei Status on the Growth Kinetics of Human Mesenchymal Stem Cells
Investigators examined the frequency of nuclear blebs (NBs) and micronuclei (MNs) in mesenchymal stem cells (MSCs) from umbilical cord and placenta and found a difference in the number of NBs and MNs depending on the source of the MSCs. [J Cell Physiol] Abstract

Amniotic Fluid Stem Cells Prevent Follicle Atresia and Rescue Fertility of Mice with Premature Ovarian Failure Induced by Chemotherapy
Investigators isolated amniotic fluid stem cells (AFSCs) from transgenic mice that ubiquitously express enhanced green fluorescence protein. These AFSCs exhibited morphologies, immunophenotypes, and mesoderm trilineage differentiation potentials similar to mesenchymal stem cells. [PLoS One] Full Article

Outcomes and Management Strategies for Graft Failure after Umbilical Cord Blood Transplantation
Graft failure is more prevalent after umbilical cord blood transplantation (UCBT) compared to conventional adult stem cell sources. Investigators identified 21 consecutive patients who experienced graft failure after UCBT at their center describe their treatment strategies and outcomes. [Am J Hematol] Abstract

Superselective Intra-Arterial Umbilical Cord Blood Administration to BM in Experimental Animals
The authors investigated whether umbilical cord blood (UCB) could be administered safely using superselective intra-arterial injection. They injected human UCB into the aorta in rats, into the iliac artery in mice and into the femoral nutrient artery in rabbits. [Bone Marrow Transplant] Full Article

Priming Wharton’s Jelly-Derived Mesenchymal Stromal/Stem Cells with ROCK Inhibitor Improves Recovery in an Intracerebral Hemorrhage Model
A strategy of priming mesenchymal stromal/stem cells (MSCs) with fasudil, a Rho-kinase inhibitor, was investigated using Wharton’s jelly-derived MSCs to improve recovery in a rat model of intracranial hemorrhage. [J Cell Biochem] Abstract

Improved Differentiation of Umbilical Cord Blood-Derived Mesenchymal Stem Cells into Insulin-Producing Cells by PDX-1 mRNA Transfection
Investigators aimed to establish a new method to induce PDX-1 expression in mesenchymal stem cells (MSCs) by messenger RNA (mRNA) transfection. MSCs were isolated from human umbilical cord blood and expanded in vitro, with stemness confirmed by surface markers and multipotentiality. [Differentiation] Abstract

Haploidentical Hematopoietic Stem Cell Transplant with Umbilical Cord-Derived Multipotent Mesenchymal Cell Infusion for the Treatment of High-Risk Acute Leukemia in Children
25 children with high-risk acute leukemia received haploidentical hematopoietic stem cell transplant with co-transfusion of umbilical cord multipotent mesenchymal cells. Adverse effects, hematopoietic recovery, complications and outcome were observed during a median follow-up of 12.8 months. [Leuk Lymphoma] Abstract

BMP-7 Improved Proliferation and Hematopoietic Reconstitution Potential of Ex Vivo Expanded Cord Blood-Derived CD34+ Cells
The effects of bone morphogenetic protein (BMP)-2 and BMP-7 at different doses on expansion, clonogenicity and differentiation of cord blood-derived CD34+ cells were investigated in serum-free medium supplemented with stem cell factor, thrombopoietin and flt3-ligand. [Hum Cell] Abstract

New StemSpan(TM) SFEM II - for optimal CD34+ cell expansion of bone marrow and cord blood cells
Hematopoietic Stem Cell Transplantation for Sickle Cell Disease: State of the Science
The authors discuss the most recent advances in allogeneic stem cell transplantation in patients with sickle cell disease including more novel approaches such as reduced toxicity conditioning and the use of alternative allogeneic donors, including matched unrelated, unrelated cord blood donors, and familial haploidentical donors. [Eur J Haematol] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.
Cellerant Awarded $47.5 Million under Existing U.S. Government Contract to Support Development of CLT-008
Cellerant Therapeutics Inc. announced that it has been awarded $47.5 million under a second option exercised by the Biomedical Advanced Research and Development Authority. The award will support the continued advanced development of CLT-008, a first-in-class, allogeneic, cell-based therapy for the treatment of hematopoietic sub-syndrome of acute radiation syndrome. [Cellerant Therapeutics Inc. (GlobeNewswire, Inc.)] Press Release

BioLineRx Doses First Patient for BL-8040’s Second Indication as Novel Stem Cell Mobilization Treatment
BioLineRx Ltd. announced dosing of the first patient in a Phase I trial for a second indication of its BL-8040 cancer therapy platform, as a novel treatment for the mobilization of stem cells from the bone marrow to the peripheral blood circulation, where they can be harvested for transplant supporting the treatment of hematological indications. [BioLineRx Ltd.] Press Release

From our sponsor:
View immunology lectures, protocols and other resources on the
Human Immunology Portal.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Lymphoma & Myeloma 2014: An International Congress on Hematologic Malignancies
October 23-25, 2014
New York City, United States

Visit our events page to see a complete list of events in the cord blood community.
NEW PhD Positions – Stem Cells and Transplantation (University of Geneva)

Postdoctoral Fellow – Hematopoietic Stem Cells and Signaling Transduction (University of Pennsylvania)

Postdoctoral Fellow – Signaling in Hematopoiesis & Leukemia (Albert Einstein College of Medicine of Yeshiva University)

Research Assistant – Ex Vivo Cord Blood Expansion (MD Anderson Cancer Center)

Postdoctoral Positions – Hematopoietic and Induced Pluripotent Stem Cells (Indiana University School of Medicine)

Postdoctoral Positions – Hematologic Malignancies and Cellular Therapy (Duke University Department of Medicine)

Postdoctoral Fellowship – Developing Applications of Mesenchymal Stromal/Stem Cells in Hematopoietic Cell Transplantation (The Research Institute at Nationwide Children’s Hospital)

Postdoctoral Positions – Reprogramming and Genetic Engineering Technologies to Develop New Models of Hematopoiesis and Hematopoietic Disorders (Icahn School of Medicine)

Cord Tissue Processing Technician (Cord Blood Registry)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Cord Blood News: Archives | Events | Contact Us